Atara Biotherapeutics, Inc.
NASDAQ:ATRA
Overview | Financials
| Company Name | Atara Biotherapeutics, Inc. |
| Symbol | ATRA |
| Currency | USD |
| Price | 12.18 |
| Market Cap | 85,540,505 |
| Dividend Yield | 0% |
| 52-week-range | 5.005 - 18.705 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. Pascal Touchon D.V.M. |
| Website | https://www.atarabio.com |
An error occurred while fetching data.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD








